Literature DB >> 7400264

High-performance liquid chromatographic analysis of dipyridamole in plasma and whole blood.

K M Wolfram, T D Bjornsson.   

Abstract

A rapid, sensitive, and specific high-performance liquid chromatographic method is described for the quantitative analysis of dipyridamole in plasma and whole blood. The method involves a single extraction of an alkalinized sample with diethyl ether followed by evaporation of the organic solvent and ion-pair chromatography using fluorescence detection. The lower limit of sensitivity for dipyridamole is 1 ng/ml. Concentrations of dipyridamole between 1 and 500 ng per sample are measured with an average coefficient of variation of 4.5% in plasma and 7.4% in whole blood.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7400264     DOI: 10.1016/s0378-4347(00)81398-5

Source DB:  PubMed          Journal:  J Chromatogr


  7 in total

1.  Dipyridamole: pharmacokinetics and effects on aspects of platelet function in man.

Authors:  D Gregov; A Jenkins; E Duncan; D Siebert; S Rodgers; B Duncan; F Bochner; J Lloyd
Journal:  Br J Clin Pharmacol       Date:  1987-10       Impact factor: 4.335

2.  A phase II trial of PALA + dipyridamole in patients with advanced soft-tissue sarcoma.

Authors:  E S Casper; J Baselga; T B Smart; G B Magill; M Markman; A Ranhosky
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

3.  Effect of dipyridamole on fluorodeoxyuridine cytotoxicity in vitro and in cancer patients.

Authors:  A C Buzaid; D S Alberts; J Einspahr; K Mosley; Y M Peng; K Tutsch; C P Spears; H S Garewal
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  Pharmacologic basis for the use of dipyridamole to increase the selectivity of intraperitoneally delivered methotrexate.

Authors:  R Goel; R Sanga; S B Howell
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

5.  Effects of platelet-modifying drugs on arterial thromboembolism in baboons. Aspirin potentiates the antithrombotic actions of dipyridamole and sulfinpyrazone by mechanism(s) independent of platelet cyclooxygenase inhibition.

Authors:  S R Hanson; L A Harker; T D Bjornsson
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

6.  Oral dipyridamole and methotrexate in human solid tumors: a toxicity trial.

Authors:  C S Higano; R B Livingston
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

7.  pH-related changes in the absorption of dipyridamole in the elderly.

Authors:  T L Russell; R R Berardi; J L Barnett; T L O'Sullivan; J G Wagner; J B Dressman
Journal:  Pharm Res       Date:  1994-01       Impact factor: 4.200

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.